Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF
暂无分享,去创建一个
R. Speck | J. van Lunzen | S. Shreay | J. Arribas | J. Gathe | R. Bender | W. Garner | Thai Nguyen